Gibson Christopher sold $123K of RXRX

Gibson Christopher sold 40,000 shares of RECURSION PHARMACEUTICALS, INC. (RXRX) at $3.08 ($0.12M total) on 2026-05-22 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Gibson Christopher
Published May 27, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 27, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RXRX
Neutral
high confidence
Mentioned
$RXRX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RXRXNeutralLow
01

Why it matters

Because the sale is explicitly pre-arranged, it is less likely to reflect new negative information; however, it can still affect short-term sentiment around RXRX.

02

Market read

Trading relevance is mainly sentiment/positioning rather than a fundamental catalyst.

03

What to watch

Check whether there are multiple recent insider sales/buys and whether the 10b5-1 plan cadence is accelerating or consistent with prior filings.

Relevance 6/10Timing: Same-day disclosure (filed 2026-05-27) may cause brief sentiment/positioning effects, but not a catalyst.

Background

The article reports a Form 4 insider transaction: director Gibson Christopher sold RXRX shares on 2026-05-22 under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$RXRXNeutralHigh confidence
Context

Recursion Pharmaceuticals director Gibson Christopher sold 40,000 shares in an open-market transaction worth $123,200 under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited immediate price impact; any move would be more about broader RXRX news flow than this Form 4.

Evidence & confidence

The filing is a scheduled 10b5-1 sale with no stated linkage to company events (no earnings, trial, deal, or regulatory action).

Market effects

Minimal; insider 10b5-1 sales are common in biotech and usually don’t reset sector expectations without accompanying operational news.

None indicated; this is a US-listed company insider transaction.

None indicated; no cross-border deal, regulator, or trial update mentioned.

Counterpoint

If RXRX is already under pressure, incremental insider selling headlines can amplify bearish positioning even when the sale is pre-planned.

Key entities

  • Recursion Pharmaceuticals, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Gibson Christopher

    Director who sold 40,000 RXRX shares for $123,200 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RXRXMed

Recursion Aligns With FDA On Phase 3 Trial Design For FAP Drug REC-4881; Stock Up

Recursion Pharmaceuticals (RXRX) aligned with the FDA on the Phase 3 trial design for REC-4881, an oral MEK1/2 inhibitor for familial adenomatous polyposis (FAP). The trial, expected to start in late 2027, will assess composite event-free survival as the primary endpoint. REC-4881 has shown a 47% median reduction in total polyp burden in Phase 1b/2 trials. RXRX shares were up 4.41% in premarket trading.

$RXRXMedAI 8/10

Recursion (RXRX) Q3 2026 Earnings Call Transcript

Recursion (RXRX) reported Q3 2026 earnings, highlighting clinical data for REC-4881 and REC-1245. REC-4881 showed significant reductions in polyp burden and safety. REC-1245 demonstrated early activity in solid tumors. The company secured $535M in partner cash inflows and extended cash runway to 2029. Operating expenses for 2026 were lowered to $375M, with 2027 expected under $360M. Sanofi and Roche collaborations advanced, with milestones and royalties. Fred Hassan was appointed board chair.

$RXRXMedAI 8/10

What Recursion Pharmaceuticals (RXRX) Said on Its Q3 Earnings Call

Recursion Pharmaceuticals (RXRX) reported Q3 updates, including 55% and 50% median reductions in upper and lower GI polyp burdens, respectively. REC-1245 showed partial responses in advanced solid tumors. Sanofi exercised an option, triggering a $10M payment. RXRX raised $200M in financing, extending cash runway into 2029. The company expects to start a registrational study in 2H 2027.

$RXRXHighAI 8/10

Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues

Recursion Pharmaceuticals reported a narrower-than-expected Q3 2026 loss of 22 cents per share, with revenues of $18.55 million, up 258.5% YoY, driven by a $10 million Sanofi milestone payment. Operating expenses declined, and the company advanced its pipeline, including REC-4881 and REC-1245. RXRX shares are down 6.4% YTD.